Active — Not RecruitingNot Applicable

Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

United States18 participantsStarted 2026-02-19

Plain-language summary

The goal of this clinical trial is to investigate the usability of auto-captioning glasses for adults diagnosed with NF2-related schwannomatosis and loss of hearing. The primary objective of the study is to determine the feasibility and acceptability of auto-captioning glasses in this population. Participants will be asked to: * Use the glasses at their discretion for 12 weeks * Report their feedback at 3 and 12 week timepoints via online surveys and remote qualitative interviews

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of NF2-SWN by 2022 revised criteria * Age 18 years or older at time of consent * Willing and able to sign informed consent * Access to a mobile phone with current operating software (i.e., iOS 16+ or Android 12+) and an internet connection * Does not require prescription glasses to communicate others (e.g. may use reading glasses or similar) * Resident of the U.S. * English-speaking Exclusion Criteria: * Current use of auto-captioning glasses

What they're measuring

System Usability Scale

Timeframe: 12 Weeks

Trial details

NCT IDNCT07420751

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More NF2-related Schwannomatosis trials